<HashMap><database>biostudies-literature</database><scores/><additional><omics_type>Unknown</omics_type><volume>225(3)</volume><submitter>Ryan KA</submitter><funding>AstraZeneca</funding><pubmed_abstract>Cocirculation of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and influenza viruses could pose unpredictable risks to health systems globally, with recent studies suggesting more severe disease outcomes in coinfected patients. The initial lack of a readily available coronavirus disease 2019 (COVID-19) vaccine has reinforced the importance of influenza vaccine programs during the COVID-19 pandemic. Live attenuated influenza vaccine (LAIV) is an important tool in protecting against influenza, particularly in children. However, it is unknown whether LAIV administration influences the outcomes of acute SARS-CoV-2 infection or disease. To investigate this, quadrivalent LAIV was administered to ferrets 3 days before or after SARS-CoV-2 infection. LAIV administration did not exace</pubmed_abstract><journal>The Journal of infectious diseases</journal><pagination>404-412</pagination><full_dataset_link>https://www.ebi.ac.uk/biostudies/studies/S-EPMC8689863</full_dataset_link><repository>biostudies-literature</repository><pubmed_title>Sequential Delivery of Live Attenuated Influenza Vaccine and Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) in the Ferret Model Can Reduce SARS-CoV-2 Shedding and Does Not Result in Enhanced Lung Pathology.</pubmed_title><pmcid>PMC8689863</pmcid><pubmed_authors>Ryan KA</pubmed_authors><pubmed_authors>Rayner E</pubmed_authors><pubmed_authors>Watson RJ</pubmed_authors><pubmed_authors>Crowe J</pubmed_authors><pubmed_authors>Marriott AC</pubmed_authors><pubmed_authors>Fotheringham SA</pubmed_authors><pubmed_authors>Whittaker CJ</pubmed_authors><pubmed_authors>Dibben O</pubmed_authors><pubmed_authors>Salguero FJ</pubmed_authors><pubmed_authors>Hall Y</pubmed_authors><pubmed_authors>Humphreys R</pubmed_authors><pubmed_authors>Carroll MW</pubmed_authors><pubmed_authors>Paterson J</pubmed_authors><pubmed_authors>Schewe KE</pubmed_authors></additional><is_claimable>false</is_claimable><name>Sequential Delivery of Live Attenuated Influenza Vaccine and Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) in the Ferret Model Can Reduce SARS-CoV-2 Shedding and Does Not Result in Enhanced Lung Pathology.</name><description>Cocirculation of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and influenza viruses could pose unpredictable risks to health systems globally, with recent studies suggesting more severe disease outcomes in coinfected patients. The initial lack of a readily available coronavirus disease 2019 (COVID-19) vaccine has reinforced the importance of influenza vaccine programs during the COVID-19 pandemic. Live attenuated influenza vaccine (LAIV) is an important tool in protecting against influenza, particularly in children. However, it is unknown whether LAIV administration influences the outcomes of acute SARS-CoV-2 infection or disease. To investigate this, quadrivalent LAIV was administered to ferrets 3 days before or after SARS-CoV-2 infection. LAIV administration did not exace</description><dates><release>2022-01-01T00:00:00Z</release><publication>2022 Feb</publication><modification>2026-05-08T06:26:02.137Z</modification><creation>2026-04-07T23:41:40.478Z</creation></dates><accession>S-EPMC8689863</accession><cross_references><pubmed>34893851</pubmed><doi>10.1093/infdis/jiab594</doi></cross_references></HashMap>